Limits...
Therapeutic potential of human adipose-derived stem cells (ADSCs) from cancer patients: a pilot study.

García-Contreras M, Vera-Donoso CD, Hernández-Andreu JM, García-Verdugo JM, Oltra E - PLoS ONE (2014)

Bottom Line: Mesenchymal stem cells from adipose tissue (ADSCs) are an important source of cells for regenerative medicine.Cancer patients, specifically those undergoing invasive surgery, constitute a subgroup of patients who could benefit from autologous stem cell transplantation.Molecular karyotyping of patient expanded ADSCs genomes showed no disease-related alterations indicating their safety.

View Article: PubMed Central - PubMed

Affiliation: Facultad de Medicina, Universidad Católica de Valencia "San Vicente Mártir", Valencia, Spain.

ABSTRACT
Mesenchymal stem cells from adipose tissue (ADSCs) are an important source of cells for regenerative medicine. The therapeutic effect of culture-expanded adipose derived stem cells has been shown; however, optimal xeno-free culture conditions remain to be determined. Cancer patients, specifically those undergoing invasive surgery, constitute a subgroup of patients who could benefit from autologous stem cell transplantation. Although regenerative potential of their ADSCs could be affected by the disease and/or treatment, we are not aware of any study that has evaluated the therapeutic potential of ADSCs isolated from cancer patients in reference to that of ADSCs derived from healthy subjects. Here we report that ADSCs isolated from subabdominal adipose tissue of patients with urological neoplasms yielded similar growth kinetics, presented equivalent mesenchymal surface markers and showed similar differentiation potential into distinct mesodermal cell lineages: adipocytes, chondroblasts and osteoblasts than ADSCs isolated from adipose tissue of age-matched non-oncogenic participants, all under xeno-free growth culture conditions. Molecular karyotyping of patient expanded ADSCs genomes showed no disease-related alterations indicating their safety. In addition, vesicles <100 nm identified as exosomes (EXOs) which may be at least partly responsible for the attributed therapeutic paracrine effects of the ADSCs were effectively isolated from ADSCs and showed equivalent miRNA content regardless they were derived from cancer patients or non-oncogenic participants indicating that the repair capabilities of xeno-free expanded ADSCs are not compromised by patient condition and therefore their xeno-free culture expanded ADSCs should be suitable for autologous stem cell transplantation in a clinical setting.

Show MeSH

Related in: MedlinePlus

Growth kinetics of ADSCs.Results are presented as cumulative populating doublings of ADSCs derived from five different cancer patients and two non-tumorigenic participants (donors) under xeno-free culture conditions. Cell numbers were determined at the end of every passage and cumulative population doublings were calculated as described in Materials and Methods.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4239050&req=5

pone-0113288-g001: Growth kinetics of ADSCs.Results are presented as cumulative populating doublings of ADSCs derived from five different cancer patients and two non-tumorigenic participants (donors) under xeno-free culture conditions. Cell numbers were determined at the end of every passage and cumulative population doublings were calculated as described in Materials and Methods.

Mentions: To investigate cell growth potential of cells from either group of participants, population doublings (PD) of each sample were determined at every passage up to passage 6, equivalent to day 58 in culture on average (Figure 1). The difference between patients (6.292±1.394) and donor (4.869±1.801) PDs was not significant (p>0.5), as determined by unpaired t-test analysis of the data. Semi-confluence at passage 1 varied about 3.6±1.2 PD for patients and 2.02±1.7 PD for non-oncogenic participants (Figure 1), coinciding with previous reports [31]–[33].


Therapeutic potential of human adipose-derived stem cells (ADSCs) from cancer patients: a pilot study.

García-Contreras M, Vera-Donoso CD, Hernández-Andreu JM, García-Verdugo JM, Oltra E - PLoS ONE (2014)

Growth kinetics of ADSCs.Results are presented as cumulative populating doublings of ADSCs derived from five different cancer patients and two non-tumorigenic participants (donors) under xeno-free culture conditions. Cell numbers were determined at the end of every passage and cumulative population doublings were calculated as described in Materials and Methods.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4239050&req=5

pone-0113288-g001: Growth kinetics of ADSCs.Results are presented as cumulative populating doublings of ADSCs derived from five different cancer patients and two non-tumorigenic participants (donors) under xeno-free culture conditions. Cell numbers were determined at the end of every passage and cumulative population doublings were calculated as described in Materials and Methods.
Mentions: To investigate cell growth potential of cells from either group of participants, population doublings (PD) of each sample were determined at every passage up to passage 6, equivalent to day 58 in culture on average (Figure 1). The difference between patients (6.292±1.394) and donor (4.869±1.801) PDs was not significant (p>0.5), as determined by unpaired t-test analysis of the data. Semi-confluence at passage 1 varied about 3.6±1.2 PD for patients and 2.02±1.7 PD for non-oncogenic participants (Figure 1), coinciding with previous reports [31]–[33].

Bottom Line: Mesenchymal stem cells from adipose tissue (ADSCs) are an important source of cells for regenerative medicine.Cancer patients, specifically those undergoing invasive surgery, constitute a subgroup of patients who could benefit from autologous stem cell transplantation.Molecular karyotyping of patient expanded ADSCs genomes showed no disease-related alterations indicating their safety.

View Article: PubMed Central - PubMed

Affiliation: Facultad de Medicina, Universidad Católica de Valencia "San Vicente Mártir", Valencia, Spain.

ABSTRACT
Mesenchymal stem cells from adipose tissue (ADSCs) are an important source of cells for regenerative medicine. The therapeutic effect of culture-expanded adipose derived stem cells has been shown; however, optimal xeno-free culture conditions remain to be determined. Cancer patients, specifically those undergoing invasive surgery, constitute a subgroup of patients who could benefit from autologous stem cell transplantation. Although regenerative potential of their ADSCs could be affected by the disease and/or treatment, we are not aware of any study that has evaluated the therapeutic potential of ADSCs isolated from cancer patients in reference to that of ADSCs derived from healthy subjects. Here we report that ADSCs isolated from subabdominal adipose tissue of patients with urological neoplasms yielded similar growth kinetics, presented equivalent mesenchymal surface markers and showed similar differentiation potential into distinct mesodermal cell lineages: adipocytes, chondroblasts and osteoblasts than ADSCs isolated from adipose tissue of age-matched non-oncogenic participants, all under xeno-free growth culture conditions. Molecular karyotyping of patient expanded ADSCs genomes showed no disease-related alterations indicating their safety. In addition, vesicles <100 nm identified as exosomes (EXOs) which may be at least partly responsible for the attributed therapeutic paracrine effects of the ADSCs were effectively isolated from ADSCs and showed equivalent miRNA content regardless they were derived from cancer patients or non-oncogenic participants indicating that the repair capabilities of xeno-free expanded ADSCs are not compromised by patient condition and therefore their xeno-free culture expanded ADSCs should be suitable for autologous stem cell transplantation in a clinical setting.

Show MeSH
Related in: MedlinePlus